Decreased expression of Apaf-1 with progression of melanoma

Rita Mustika1, Arief Budiyanto, Chikako Nishigori

  • 1Division of Dermatology, Clinical Molecular Medicine, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Pigment Cell Research
|January 15, 2005
PubMed

Insights

Melanoma cells lose Apoptotic protease-activating factor-1 (Apaf-1) protein as tumors progress, leading to chemotherapy resistance. Reduced Apaf-1 expression correlates with advanced melanoma stages, including metastases.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Pathology

Background:

  • Defects in the apoptotic system are implicated in melanoma pathogenesis and chemotherapy resistance.
  • Apoptotic protease-activating factor-1 (Apaf-1) is crucial for apoptosis, working with cytochrome c and caspase-9.
  • Metastatic melanomas frequently exhibit Apaf-1 loss and apoptosis resistance.

Purpose of the Study:

  • To investigate whether Apaf-1 protein is lost during melanoma progression from localized to metastatic stages.
  • To determine the correlation between Apaf-1 expression levels and melanoma pathological stage.

Main Methods:

  • Immunohistochemistry was used to evaluate Apaf-1 protein expression.
  • Apaf-1 expression was assessed in various melanoma lesions: nevi, melanomas in situ, primary melanomas, and metastases.

Main Results:

  • A significant decrease in Apaf-1 expression was observed when comparing nevi and melanomas (P < 0.0001).
  • Primary melanomas with greater tumor thickness showed reduced Apaf-1 expression (P < 0.003).
  • Apaf-1 expression was undetectable in metastatic melanoma lesions.

Conclusions:

  • There is an inverse correlation between Apaf-1 expression and the pathological stage of melanoma.
  • Decreased Apaf-1 expression during melanoma progression likely contributes to increased chemotherapy resistance.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...